Abstract

To investigate the efficacy and prognostic factors in patients with stage Ib and IIa cervical carcinoma by radical radiotherapy. Between January 1999 and January 2012, 108 patients with stage Ib and IIa cervical carcinoma received radical radiotherapy in Cancer Hospital, Chinese Academy of Medical Sciences were included and analyzed retrospectively. Patients of stage Ib1, Ib2, IIa1 and IIa2 were 18 (16.7%, 18/108), 38 (35.2%, 38/108), 33 (30.6%, 33/108) and 19 (17.6%, 19/108), respectively. The 5-year overall survival rate was 76.2% and the 5-year disease free survival rate was 75.6%. Totally 25 (23.1%, 25/108) patients developed recurrent disease, 16 of them (64%, 16/25) had local recurrences, 6 (24%, 6/25) had distant metastases and 3 cases had both local recurrence and distant metastases. Among patients with recurrent disease, 23 died and 2 survive with tumor. Totally 24 patients died, 23 of them died due to tumor recurrence and the other one died of other reason. The univariate analysis showed that, lymph node metastasis, squamous cell carcinoma antigen (SCC) levels before treatment, SCC levels after treatment 1 month had relation with overall survival time in patients with stage Ib and IIa cervical carcinoma (all P < 0.05). The multivariate analysis showed that, lymph node metastasis and SCC levels after treatment 1 month were the independent prognostic factors for overall survival time for the cervical squamous cell carcinoma (OR = 2.5, 4.4; all P < 0.05). By means of radical radiotherapy, stageIb and IIa cervical carcinoma patients with lymph node metastasis and SCC levels ≥ 1.5 mg/L after treatment one month have poor prognosis.While, stageIb and IIa patients with concurrent chemoradiotherapy after neoadjuvant chemotherapy did not affect the prognosis. The 5-year survival rate with concurrent chemoradiotherapy was higher than that of radiotherapy.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call